Reimagining Cancer Immunotherapy
What We Do
EvolveImmune is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation. The EVOLVE platform tackles the treatment challenges of cancer cell resistance to current immunotherapies. The company’s lead internal drug candidate, EVOLVE104, will enter the clinic in 2025.
EvolveImmune has also partnered with Abbvie to develop additional therapeutics that leverage the power of costimulation.
Who We Are
We are driven by a common purpose to improve the lives of cancer patients and their families. This inspires our innovative spirit, arouses our curiosity, and fuels our relentlessness.